Literature DB >> 24460818

Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients.

J Saison1, T Ferry, J Demaret, D Maucort Boulch, F Venet, T Perpoint, F Ader, V Icard, C Chidiac, G Monneret.   

Abstract

The mechanisms sustaining the absence of complete immune recovery in HIV-infected patients upon long-term effective highly active anti-retroviral therapy (HAART) remain elusive. Immune activation, regulatory T cells (T(regs)) or very low-level viraemia (VLLV) have been alternatively suspected, but rarely investigated simultaneously. We performed a cross-sectional study in HIV-infected aviraemic subjects (mean duration of HAART: 12 years) to concomitantly assess parameters associated independently with inadequate immunological response. Patients were classified as complete immunological responders (cIR, n = 48) and inadequate immunological responders (iIR, n = 39), depending on the CD4(+) T cell count (> or < 500/mm(3)). Clinical and virological data (including very low-level viraemia) were collected. In parallel, immunophenotyping of CD4(+) lymphocytes, including T(reg) subsets, and CD8(+) T cells was performed. Percentages of activated CD4(+) T cells, T(regs), effector T(regs) and terminal effector T(regs) were found to be significantly elevated in iIR. Neither the percentage of activated CD8(+) T cells nor VLLV were found to be associated with iIR. In the multivariate analysis, nadir of CD4(+) T cell count and percentage of T(regs) were the only two parameters associated independently with iIR [odds ratio (OR) = 2·339, P = 0·001, and OR = 0·803, P = 0·041]. We present here the largest study investigating simultaneously the immune response to long-term HAART, activation of CD4(+) and CD8(+) T cells, T(reg) percentages and very low-level viraemia. Causative interactions between T(regs) and CD4(+) T cells should now be explored prospectively in a large patients cohort.
© 2014 British Society for Immunology.

Entities:  

Keywords:  HAART; immune activation; immunological response; regulatory T cells; very low-level viraemia

Mesh:

Substances:

Year:  2014        PMID: 24460818      PMCID: PMC4008985          DOI: 10.1111/cei.12278

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  59 in total

1.  Assessment of a novel flow cytometry technique of one-step intracellular staining: example of FOXP3 in clinical samples.

Authors:  Julie Demaret; Julien Saison; Fabienne Venet; Christophe Malcus; Francoise Poitevin-Later; Alain Lepape; Tristan Ferry; Guillaume Monneret
Journal:  Cytometry B Clin Cytom       Date:  2013-01-16       Impact factor: 3.058

2.  Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy.

Authors:  Taisheng Li; Ning Wu; Yi Dai; Zhifeng Qiu; Yang Han; Jing Xie; Ting Zhu; Yanling Li
Journal:  Clin Infect Dis       Date:  2011-09-29       Impact factor: 9.079

3.  Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study.

Authors:  R J C Gilson; S-L Man; A Copas; A Rider; S Forsyth; T Hill; L Bansi; K Porter; B Gazzard; C Orkin; D Pillay; A Schwenk; M Johnson; P Easterbook; J Walsh; M Fisher; C Leen; J Anderson; C A Sabin
Journal:  HIV Med       Date:  2009-09-01       Impact factor: 3.180

4.  Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients.

Authors:  Meenakshi Sachdeva; Margaret A Fischl; Rajendra Pahwa; Naresh Sachdeva; Savita Pahwa
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

5.  Regulatory T cells and chronic immune activation in human immunodeficiency virus 1 (HIV-1)-infected children.

Authors:  R Freguja; K Gianesin; I Mosconi; M Zanchetta; F Carmona; O Rampon; C Giaquinto; A De Rossi
Journal:  Clin Exp Immunol       Date:  2011-03-25       Impact factor: 4.330

6.  Regulatory T cells in human immunodeficiency virus-infected patients are elevated and independent of immunological and virological status, as well as initiation of highly active anti-retroviral therapy.

Authors:  J C Gaardbo; S D Nielsen; S J Vedel; A K Ersbøll; L Harritshøj; L P Ryder; J O Nielsen; L Kolte
Journal:  Clin Exp Immunol       Date:  2008-10       Impact factor: 4.330

Review 7.  Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.

Authors:  Mario P Colombo; Silvia Piconese
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

8.  Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation.

Authors:  Amanda J Chase; Hung-Chih Yang; Hao Zhang; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

9.  The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value.

Authors:  M Levacher; F Hulstaert; S Tallet; S Ullery; J J Pocidalo; B A Bach
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

10.  Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.

Authors:  Andrew Lim; Dino Tan; Patricia Price; Adeeba Kamarulzaman; Hong-Yien Tan; Ian James; Martyn A French
Journal:  AIDS       Date:  2007-07-31       Impact factor: 4.177

View more
  14 in total

1.  Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Authors:  Emily C Liang; Lindsay Sceats; Nicholas L Bayless; Dara M Strauss-Albee; Jessica Kubo; Philip M Grant; David Furman; Manisha Desai; David A Katzenstein; Mark M Davis; Andrew R Zolopa; Catherine A Blish
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

2.  Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.

Authors:  Nadejda Beliakova-Bethell; Sonia Jain; Christopher H Woelk; Mallory D Witt; Xiaoying Sun; Steven M Lada; Celsa A Spina; Miguel Goicoechea; Steffney E Rought; Richard Haubrich; Michael P Dubé
Journal:  Antiviral Res       Date:  2014-04-24       Impact factor: 5.970

Review 3.  Current views on HIV-1 latency, persistence, and cure.

Authors:  Zora Melkova; Prakash Shankaran; Michaela Madlenakova; Josef Bodor
Journal:  Folia Microbiol (Praha)       Date:  2016-10-05       Impact factor: 2.099

4.  Persistent production of an integrase-deleted HIV-1 variant with no resistance mutation and wild-type proviral DNA in a treated patient.

Authors:  Mary-Anne Trabaud; Laurent Cotte; Julien Saison; Christophe Ramière; Corinne Ronfort; Fabienne Venet; Jean-Claude Tardy; Guillaume Monneret; Patrice André
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 5.  Residual inflammation and viral reservoirs: alliance against an HIV cure.

Authors:  Marta Massanella; Rémi Fromentin; Nicolas Chomont
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

6.  Increased Regulatory T-Cell Percentage Contributes to Poor CD4(+) Lymphocytes Recovery: A 2-Year Prospective Study After Introduction of Antiretroviral Therapy.

Authors:  Julien Saison; Delphine Maucort Boulch; Christian Chidiac; Julie Demaret; Christophe Malcus; Laurent Cotte; Francoise Poitevin-Later; Patrick Miailhes; Fabienne Venet; Mary Anne Trabaud; Guillaume Monneret; Tristan Ferry
Journal:  Open Forum Infect Dis       Date:  2015-05-01       Impact factor: 3.835

7.  Systemic Cytokine Levels Do Not Predict CD4(+) T-Cell Recovery After Suppressive Combination Antiretroviral Therapy in Chronic Human Immunodeficiency Virus Infection.

Authors:  Philip J Norris; Jinbing Zhang; Andrew Worlock; Sangeetha V Nair; Kathryn Anastos; Howard L Minkoff; Maria C Villacres; Mary Young; Ruth M Greenblatt; Seema Desai; Alan L Landay; Stephen J Gange; C Thomas Nugent; Elizabeth T Golub; Sheila M Keating
Journal:  Open Forum Infect Dis       Date:  2016-02-08       Impact factor: 3.835

8.  Longitudinal evaluation of regulatory T-cell dynamics on HIV-infected individuals during the first 2 years of therapy.

Authors:  Claudia Nobrega; Ana Horta; Vítor Coutinho-Teixeira; Ana Martins-Ribeiro; Ana Baldaia; Rita Rb-Silva; Catarina L Santos; Rui Sarmento-Castro; Margarida Correia-Neves
Journal:  AIDS       Date:  2016-05-15       Impact factor: 4.177

9.  Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort Study.

Authors:  Mariam Noelie Hema; Tristan Ferry; Michel Dupon; Lise Cuzin; Renaud Verdon; Rodolphe Thiébaut; Camelia Protopopescu; Catherine Leport; François Raffi; Vincent Le Moing
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.240

Review 10.  Targeting regulatory T cells to improve vaccine immunogenicity in early life.

Authors:  Jorjoh Ndure; Katie L Flanagan
Journal:  Front Microbiol       Date:  2014-09-11       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.